Mason Carrico

Stock Analyst at Stephens & Co.

(3.56)
# 907
Out of 5,182 analysts
71
Total ratings
45.59%
Success rate
8.13%
Average return

Stocks Rated by Mason Carrico

Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197$235
Current: $208.40
Upside: +12.76%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8$2
Current: $1.69
Upside: +18.34%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5$11
Current: $8.35
Upside: +31.74%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $35.68
Upside: +87.78%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $134.50
Upside: -21.93%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $26.08
Upside: -46.32%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $21.42
Upside: +86.74%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140$115
Current: $124.79
Upside: -7.85%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.80
Upside: +33.14%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $90.36
Upside: -39.13%
Reiterates: Overweight
Price Target: $6
Current: $4.61
Upside: +30.15%
Reiterates: Equal-Weight
Price Target: $17
Current: $25.08
Upside: -32.22%
Reiterates: Overweight
Price Target: $52
Current: $67.08
Upside: -22.48%
Reiterates: Equal-Weight
Price Target: $20
Current: $5.08
Upside: +293.70%
Reiterates: Overweight
Price Target: $41
Current: $25.05
Upside: +63.67%